Compass Therapeutics Investor Presentation Deck

CTX-009- Phase 1 Clinical Studies Summary Overall Response Rate at the Efficacious Dose (10-12.5 mg/kg) Monotherapy Combination 18.8% ORR (3/16) 23.5% ORR (4/17) COMPASS THERAPEUTICS Clinical Benefit Rate at the Efficacious Dose (10-12.5 mg/kg) Monotherapy 68.8% (11/16) Combination 76.5% (13/17) 14

View entire presentation